Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050017 | 1.00 | CA12 (0.61) | CA12CA9CA4ALBMAOB | |
| SCHEMBL22501643 | 0.88 | CA12 (0.65) | CA12CA9CA4ALBMAOB | |
| SCHEMBL17050020 | 0.87 | CA12 (0.61) | CA12CA9CA4ALBMAOB | |
| SCHEMBL12989749 | 0.87 | CA12 (0.64) | CA12CA9CA4ALBMAOB | |
| SCHEMBL11596778 | 0.83 | CA12 (0.56) | CA12CA9CA4ALBMAOB | |
| SCHEMBL24589798 | 0.82 | CA12 (0.68) | CA12CA9CA4ALBMAOB | |
| SCHEMBL11934920 | 0.82 | CA9 (0.55) | CA12CA9CA4ALBMAOB | |
| SCHEMBL8620142 | 0.81 | CA12 (0.67) | CA12CA9CA4ALBMAOB | |
| SCHEMBL11935347 | 0.81 | CA9 (0.54) | CA12CA9CA4ALBMAOB | |
| SCHEMBL17050007 | 0.81 | CA12 (0.57) | CA12CA9CA4ALBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5064756-A | MICROBIAL SUSCEPTIBILITY ASSAY USING 7-N-(AMINOACYL)-7-AMIDO-4-METHYLCOUMARINS | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 1991-11-12 | — | — | US | claimed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8227618-B2 | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | SHIONOGI & CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-5064756-A | MICROBIAL SUSCEPTIBILITY ASSAY USING 7-N-(AMINOACYL)-7-AMIDO-4-METHYLCOUMARINS | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 1991-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | CA12 3342/4885CA9 2467/4885CA4 3090/4885 |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | CA12 2987/4885CA9 2207/4885CA4 3338/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | CA12 4169/4885CA9 3152/4885CA4 3872/4885 |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | CA12 2605/4885CA9 1666/4885CA4 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.